Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-07-29

Clinical Trial Update: Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing whether MetroGel 1% delivers moisture to facial skin after a single application in rosacea patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MetroGel 1% (metronidazole)

Snippet

Sponsor: Galderma R&D | Conditions: Rosacea | Phase 4 | Status: COMPLETED